Skip to main content
OpenTrials
Completed

NCT Number: NCT00915577

Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe

Determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled Avonex syringe.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Immune System Diseases Nervous System Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must be using liquid AVONEX® to treat MS. In addition, the subject must be on liquid AVONEX® for 12 weeks prior to the Screening Visit.
  • Must have a BMI of 19 to 28 kg/m², inclusive, and a minimum body weight of 50 kg at Screening.
  • Must be able to physically demonstrate use of the device and be able to self-administer all injections.
  • Must be English speaking.
  • Must be able to understand and comply with the protocol.

Exclusion criteria

  • Abnormal screening or screening blood tests determined to be clinically significant by the investigator for: white blood count (WBC) or differential, platelet count, hemoglobin, serum creatinine, bilirubin, alanine transaminase (ALT) aspartate transaminase (AST), prothrombin time (PT).
  • Known sensitivity to dry natural rubber.
  • Treatment with other agents to treat MS symptoms or underlying disease as specified in the protocol.
  • History of severe allergic or anaphylactic reactions.
  • History of intolerance to acetaminophen (paracetamol), ibuprofen, naproxen, and aspirin that would preclude the use of at least one of these during the study.
  • Serious local infection

Other inclusion and exclusion criteria apply as per Biogen Idec Protocol

Treatment and study plan

Interferon beta-1a

Drug

30mcg, IM once-a-week

Other names: Avonex

Single-use autoinjector

Device

Single-use autoinjector with Avonex 30mcg pre-filled syringe

Primary outcomes

  1. The primary objective of the study is to determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled AVONEX® syringe

    Time frame: The study duration is 8 Weeks

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Biogen

Industry

Registry information

Official study title

An Open-Label, Multicenter Study to Determine Subject Satisfaction in Using the Single-Use Autoinjector With a Pre-Filled Liquid AVONEX® Syringe in Multiple Sclerosis Subjects

Important dates

Study start
2005
Primary completion
2006
Study completion
2006
First posted
Jun 8, 2009
Registry last updated
Jun 8, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.